Evidence map›Paper›PMID 37968707›Full record

ReviewBiomaterials research2023

Application of advanced biomaterials in photothermal therapy for malignant bone tumors.

Bo Chao, Jianhang Jiao, Lili Yang, Yang Wang, Weibo Jiang, Tong Yu, Linfeng Wang, He Liu, Han Zhang, Zhonghan Wang and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 38 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. MnBioactive materials · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Recent Advancements of Nanomedicine in Breast Cancer Surgery.International journal of nanomedicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Bo ChaoDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Jianhang JiaoDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Lili YangDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Yang WangDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Weibo JiangDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Tong YuDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Linfeng WangDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
He LiuDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Han ZhangDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China.
Zhonghan WangDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China. wangzhonghan@jlu.edu.cn.
Minfei WuDepartment of Orthopedics, The Second Hospital of Jilin University, Changchun, 130041, People's Republic of China. wumf@jlu.edu.cn.ORCID http://orcid.org/0000-0001-8230-3774
Second Affiliated Hospital of Jilin University · CN

Funding

Jilin Scientific and Technological Development Program 20210204104YYJilin Scientific and Technological Development Program YDZJ202201ZYTS135Jilin Scientific and Technological Development Program YDZJ202301ZYTS031
6 · The paper itself

Abstract

Malignant bone tumors are characterized by severe disability rate, mortality rate, and heavy recurrence rate owing to the complex pathogenesis and insidious disease progression, which seriously affect the terminal quality of patients' lives. Photothermal therapy (PTT) has emerged as an attractive adjunctive treatment offering prominent hyperthermal therapeutic effects to enhance the effectiveness of surgical treatment and avoid recurrence. Simultaneously, various advanced biomaterials with photothermal capacity are currently created to address malignant bone tumors, performing distinctive biological functions, including nanomaterials, bioceramics (BC), polymers, and hydrogels et al. Furthermore, PTT-related combination therapeutic strategies can provide more significant curative benefits by reducing drug toxicity, improving tumor-killing efficiency, stimulating anti-cancer immunity, and improving immune sensitivity relative to monotherapy, even in complex tumor microenvironments (TME). This review summarizes the current advanced biomaterials applicable in PTT and relevant combination therapies on malignant bone tumors for the first time. The multiple choices of advanced biomaterials, treatment methods, and new prospects for future research in treating malignant bone tumors with PTT are generalized to provide guidance. Malignant bone tumors seriously affect the terminal quality of patients' lives. Photothermal therapy (PTT) has emerged as an attractive adjunctive treatment enhancing the effectiveness of surgical treatment and avoiding recurrence. In this review, advanced biomaterials applicable in the PTT of malignant bone tumors and their distinctive biological functions are comprehensively summarized for the first time. Simultaneously, multiple PTT-related combination therapeutic strategies are classified to optimize practical clinical issues, contributing to the selection of biomaterials, therapeutic alternatives, and research perspectives for the adjuvant treatment of malignant bone tumors with PTT in the future.

Indexed as

Advanced biomaterialsCombination therapyHyperthermiaMalignant bone tumorsPhotothermal therapy

Identifiers

PMID37968707
PMCPMC10652612
OpenAlexW4388687455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.